Kamada Pharmaceuticals
(https://kamada.com) 📸 Data Snapshot: May 31, 2026
Information Density — The Lens
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Info Density
Power-words vs. Substance ratio.
26
Impact Weight: 30 / 100
87% Reputation
Information density is exceptionally high for a corporate site. While the homepage uses some emotional fluff like ‘EACH LIFE IS UNIQUE,’ the body substance ratio is driven by hard data, including specific revenue figures ($180.5 Million), EBITDA margins (26%), and named FDA-approved products like GLASSIA and KEDRAB. The specificity absence is nearly zero, as the site provides exact collection capacities for facilities (50,000 liters) and dividend amounts ($0.25).
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://kamada.com) Kamada – High Quality Pharmaceuticals – Kamada Pharmaceuticals
EACH LIFE IS UNIQUE Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. READ MORE [IMG: Watch the video] [H2] Latest Updates Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year May. 13, 2026 Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 May. 6, 2026 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders Mar. 31, 2026 Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas Mar. 26, 2026 Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth Mar. 11, 2026 Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy Mar. 11, 2026 [IMG: Kamada to Present at WTC Transplant Summit 2025:] [H2] UPCOMING EVENT Kamada to Present at WTC Transplant Summit 2025: Aug. 2 - 6, 2025San Francisco, CA USA [IMG: Company Presentation] [H2] UPDATED COMPANY PRESENTATION [H2] PRODUCTS Our proprietary platform technology and know-how allow us to extract and purify protein therapeutics from human plasma. OURPRODUCTS [H2] PIPELINE Kamada’s Inhaled AAT has the potential of becoming a transformational next- generation augmentation therapy for Alpha-1 Antitrypsin Deficiency patients. View Pipeline [H2] ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION [IMG: Watch the video] The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions. This video illustrates the mechanism of action of AAT, and its possible therapeutic effects. [H3] Committed to Alpha-1 Patients Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis. Read more [H3] Supporting prevention of CMV disease after solid organ transplantation Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans. Read more [H3] MORETHERAPEUTICFOCUSAREAS
2568 chars
SUB-PAGE (https://kamada.com/therapeutic-focus-areas/) Therapeutic Focus Areas – Kamada Pharmaceuticals
Science [H1] Therapeutic Focus Areas [IMG: Alpha-1 Antitrypsin Deficiency] [H2] Alpha-1 Antitrypsin Deficiency Committed to Alpha-1 Patients Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis. READ MORE [IMG: CMV Disease] [H2] CMV Disease Supporting prevention of CMV disease after solid organ transplantation Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans. READ MORE [IMG: COVID-19] [H2] COVID-19 Taking part in the fight against COVID-19 Over the past months, our lives have changed dramatically as a result of the Coronavirus (COVID-19) pandemic. COVID-19 is caused by the novel virus SARS-CoV-2. As new facts about the virus and the pandemic are revealed, the international scientific community, along with the pharmaceutical industry, are making tremendous efforts in order to combat the disease. […] READ MORE [IMG: Hepatitis B recurrence after liver transplantation] [H2] Hepatitis B recurrence after liver transplantation Hepatitis B is a liver infection caused by the hepatitis B virus. It is a major global health problem. Some people with hepatitis B are sick for only a few weeks (known as an “acute” infection). Some people, especially those who get infected in adulthood, can clear the virus from their bodies without treatment. Hepatitis […] READ MORE [IMG: Rabies] [H2] Rabies Helping to prevent one of the deadliest diseases in the world Rabies is a preventable infectious viral disease that is almost always fatal following the onset of clinical symptoms. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild animals. It is spread to people through bites or scratches, usually via saliva. […] READ MORE
2048 chars
SUB-PAGE (https://kamada.com/company-profile/) Company Profile & Milestones – Kamada Pharmaceuticals
About [H1] Company Profile & Milestones Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The company’s strategy is focused on driving profitable growth from current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S. Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia.
1113 chars
SUB-PAGE (https://kamada.com/news-main/) News – Kamada Pharmaceuticals
Investors & Media [H1] News 13 May. 2026 [H3] Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company’s Products Continues to Increase, Supporting the Company’s Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 […] 6 May. 2026 [H3] Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 REHOVOT, Israel, and HOBOKEN, NJ – May 6, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the first quarter ended March […] 31 Mar. 2026 [H3] Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel, and HOBOKEN, NJ – March 31, 2026 – Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the […] 26 Mar. 2026 [H3] Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity The Center is Structured to Collect Normal Source Plasma and Specialty Plasma, […] 11 Mar. 2026 [H3] Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy REHOVOT, Israel, and HOBOKEN, NJ – March 11, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately […] 11 Mar. 2026 [H3] Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth 2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic Growth Generated $25.5 Million […] 4 Mar. 2026 [H3] Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 REHOVOT, Israel, and HOBOKEN, NJ – March 4, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year […] 7 Jan. 2026 [H3] Kamada Provides 2026 Annual Guidance of $200 – $205 Million in Revenues and $50 – $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance 2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million […] 18 Dec. 2025 [H3] Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived Products Supply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28 Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Kamada Projects Double-Digit […] 8 Dec. 2025 [H3] Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA Kamada Reiterates its 2025 Full-Year Revenue Guidance […] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
5351 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for Kamada Pharmaceuticals
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Kamada Pharmaceuticals, captured on May 31, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Kamada Pharmaceuticals: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://kamada.com to view the most current version of its content and see directly what this company is about and what it offers.